MARKET

MGTA

MGTA

Magenta Therapeutics
NASDAQ
0.8450
+0.0250
+3.05%
Pre Market: 0.8301 -0.0149 -1.76% 08:00 02/09 EST
OPEN
0.8850
PREV CLOSE
0.8200
HIGH
0.8900
LOW
0.8010
VOLUME
146
TURNOVER
--
52 WEEK HIGH
3.620
52 WEEK LOW
0.3210
MARKET CAP
51.17M
P/E (TTM)
-0.6587
1D
5D
1M
3M
1Y
5Y
BRIEF-Magenta Therapeutics Inc Says As Of Dec 31, 2022, Co's Cash, Cash Equivalents, Marketable Securities Were About $112 Mln
Reuters · 1d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 5d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 6d ago
Rapid January Jobs Growth and Weak Tech Earnings Weigh on US Equity Futures
Rapid January Jobs Growth and Weak Tech Earnings Weigh on US Equity Futures
MT Newswires · 6d ago
BRIEF-Magenta Therapeutics Inc Received Notice From Nasdaq That Co Is Not Been In Compliance With Minimum Bid Price Requirement
Reuters · 6d ago
Magenta Therapeutics up 47% on plan to pursue strategic alternatives
Seeking Alpha · 6d ago
Magenta Therapeutics To Explore Strategic Alternatives; Co. Has Made The Determination To Halt Further Development Of Its Programs And Conduct A Comprehensive Review Of Strategic Alternatives Focused On Maximizing Shareholder Value
Benzinga · 6d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 6d ago
More
About MGTA
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. It is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. The Company's pipeline of stem cell transplant product candidates consists of MGTA-145, MGTA-117, C300, C100, G100, MGTA-456 and E478. It is developing product candidates to be used individually or, in some cases, in combination with each other.

Webull offers kinds of Magenta Therapeutics Inc stock information, including NASDAQ:MGTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MGTA stock methods without spending real money on the virtual paper trading platform.